Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT07329244
Starting soon Not applicable

Graphene-Reinforced CAD/CAM Restorations for MIH-Affected Molars in Adolescents: A Prospective Clinical Study

NCT07329244 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2026-01-10
Last updated
2026-01-09

Condition(s) studied

Tooth DemineralizationTooth SensitivityEnamel Mineralization DisordersTooth Sensitivity After Composite RestorationsTooth Eruption DisorderIndirect Restoration

Investigational drug(s) / intervention(s)

Graphene-reinforced CAD/CAM polymer (G-CAM®)

Graphene-reinforced CAD/CAM polymer (G-CAM®): Graphene-reinforced CAD/CAM polymer (G-CAM®) used for the fabrication of indirect inlay, onlay, or overlay restorations in permanent molars affected by molar-incisor hypomineralization (MIH). Restorations are fabricated using a digital CAD/CAM workflow and adhesively cemented under rubber dam isolation according to the study protocol.

Study summary

This study evaluates the clinical performance, marginal integrity, surface wear, color stability, and postoperative sensitivity of graphene-reinforced CAD/CAM indirect restorations (inlays, onlays, overlays) in molars affected by moderate to severe Molar-Incisor Hypomineralization (MIH) in adolescents. A total of 30 patients aged 10-16 years will receive minimally invasive indirect restorations fabricated from a nano-reinforced graphene polymer (G-CAM®). Clinical outcomes will be assessed using FDI criteria, VAS sensitivity scores, patient satisfaction, and digital 3D scans over a 12-month follow-up. The study aims to determine clinical acceptability and safety compared with historical outcomes reported for composite and lithium-disilicate indirect restorations.

Eligibility

Sex
ALL
Min age
10 Years
Max age
16 Years
Healthy volunteers
No
Inclusion Criteria: * Adolescents aged 10-16 years. * Permanent molars with moderate or severe MIH (EAPD criteria). * Vital and restorable teeth. * Ability to attend follow-up visits. * Informed consent from guardian + assent from the minor. Exclusion Criteria: * Fluorosis, amelogenesis imperfecta, or other enamel defects. * Severe bruxism not controlled. * Active extensive caries or irreversible pulpitis. * Systemic conditions affecting enamel or healing. * Hypersensitivity/allergy to materials/adhesives. * Use of analgesics/AINEs \<24 h before baseline VAS. * Orthodontic bands on the study molar.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Dental Esthetic BCN Sarrià-Sant Gervasi Barcelona

More Universitat Internacional de Catalunya trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07329244 on ClinicalTrials.gov ↗ ← All trials in Spain